Back to results
US 11,898,175 B2Granted
Treatment of abnormal bone conditions in acid sphingomyelinase deficiency patients
AssigneeGenzyme Corporation
InventorAna Cristina Scheidt-Puga
Life of this patent
Estimating the term…
Abstract
The invention provides methods of using a human acid sphingomyelinase (e.g., olipudase alfa) in treating an abnormal bone condition in acid sphingomyelinase deficiency patients such as low bone density, high bone marrow burden, and other skeletal abnormalities presented in acid sphingomyelinase deficiency patients.
Claims11
A method of treating an abnormal bone condition in a patient with acid sphingomyelinase deficiency (ASMD), comprising:
- selecting a patient with ASMD for treatment of an abnormal bone condition,
- administering to the patient a plurality of doses of recombinant human acid sphingomyelinase (rhASM) over a period of six to thirty months,
- measuring a bone indicator of the patient, and
- comparing the bone indicator of the patient to the baseline bone indicator of the patient before the administering step, wherein the patient's bone indicator improves after the plurality of doses of rhASM.
1 more element
Dependencies are inferred from the claim text.